Onco Actu du 18 juin 2015

	1. Biologie
Organ Models on Chips [In the Pipeline] There's no reason, a priori, why the task should be impossible; it's just really hard. Worth the effort, though - what many people outside the field don't realize is how expensive and tricky running a meaningful animal study really is.
	3.1 Tabac
To Cut Teen Smoking, Raise Tobacco Sales Age [NY Times] “Our findings provide strong support for initiatives going on all across the country to increase the sales age as a means for decreasing youth access to cigarettes, initiation of smoking, and ultimately addiction.”
	4. Dépistage, diagnostic et pronostic
Beating Advanced Cancers: New Epigenomic Block for Advanced Cancer Progression [Mayo Clinic] Dr. Ho and his colleagues are currently validating a test based on the newly identified epigenomic fingerprint, called H3K36me3 loss, which could help providers identify more aggressive cancers or find the best drug for the individual patient to further personalize medical care.
	5. Traitements
Could avocados hold the key to treating leukaemia? [NHS Choices] As the research has only so far been conducted in a laboratory setting, it should be stressed that this is the beginning of a long road in drug development and may not necessarily lead to a successful treatment.
	5.12 Immunothérapies
Biotech’s Coming Cancer Cure [MIT Technology Review] Juno is located in South Lake Union, a Seattle neighborhood dominated by Amazon.com, whose CEO, Jeff Bezos, was an early investor in the company. During a day spent at Juno’s labs and offices in May, the phrase I heard repeated over and over was “proof of principle.”
	5.2 Pharma
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma [Seattle Genetics] Additional Analysis of Phase 3 AETHERA Data Demonstrates ADCETRIS Consolidation Therapy Significantly Extends Progression-Free Survival in Primary-Refractory Hodgkin Lymphoma Patients.
Servier bags EU rights to colorectal cancer drug in $130M deal [FierceBiotech] The deal concerns TAS-102, a treatment for mCRC that has already won approval in Japan and is under review in Europe and the U.S.
ImmunoGen's IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma [ImmunoGen] Later this year, ImmunoGen plans to begin assessing IMGN529 used in combination with rituximab for the treatment of relapsed/refractory DLBCL in addition to assessing it as a single agent in DLBCL and chronic lymphocytic leukemia disease-specific patient populations.
GSK to create independent research institute with goal of radically changing and improving medicines development [GSK] Altius (“higher” in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease.
	5.2.1 Pharma - Partenariats
€323m cancer deal for Irish Almac [European Biotechnology News] Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.
Lilly and Dana-Farber Cancer Institute Announce Research Collaboration [Lilly] Per the agreement, over the course of three years Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds.
Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy [Lilly] The partnership supports the development of this novel targeted cancer therapy: LY3023414, a PI3K/mTOR dual inhibitor.
	6.10 Politiques
Cancer Experts Discuss the Latest in Precision Medicine [CANCER RESEARCH Catalyst] This briefing was held to stimulate additional support for President Obama’s Precision Medicine Initiative, which has been attracting significant bipartisan backing since its announcement earlier this year.
	6.6 Publications
Science, Now Under Scrutiny Itself [NYTimes] “At this point, we see ourselves as part of an ecosystem that is advocating for increased transparency,” Dr. Oransky said. “And that ecosystem is growing.”
Widespread Data Duplication [The Scientist] Around one out of every four cancer papers scrutinized in a recent study contains questionable figures, and journals and authors aren’t responding to requests for clarification.
The Problem(s) With Credit for Peer Review [The Scholarly Kitchen] The proposed peer review credit systems currently under examination, both commercial and community-based seem like overkill.
	6.7 DMP, Big Data & applis
NHS England unveils digital roadmap [Pharmafile] NHS England has laid out digital technology plans that it says will completely transform services and improve health outcomes using technology and data.
	6.8 Communication
Everybody's talking at me, on health on Twitter [HealthNewsReview] “Our hypothesis is that cancer-specific hashtags are a promising way to facilitate access to accurate health information and positive interactions. Our aim was to retrospectively evaluate Twitter use of the Cancer Tag Ontology (CTO) and the types of users putting these hashtags into tweets.”